2025-08-19 - Analysis Report
Okay, here's a report analyzing RXRX (Recursion Pharmaceuticals Inc.) based on the provided data.

**Report: RXRX (Recursion Pharmaceuticals Inc.) Analysis**

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company using AI and machine learning to discover, develop, and commercialize novel medicines.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return:**
    *   RXRX: -45.77%
    *   VOO: 39.95%
*   **Divergence:**
    *   Current Divergence: -87.0
    *   Divergence Range: Max: 33.2, Min: -90.5
    *   Relative Divergence: 2.8

    *Analysis:* RXRX has significantly underperformed the S&P 500 (VOO) over the analyzed period. The relative divergence of 2.8 indicates that the current underperformance is near the extreme end of its historical range compared to the S&P 500.

*   **Alpha, Beta Analysis:**

| Year       | CAGR  | MDD   | Alpha   | Beta   | Cap(B) |
|------------|-------|-------|---------|--------|--------|
| 2021-2023  | 5.0%  | 73.6% | -1.0%   | -0.1   | 4.3    |
| 2022-2024  | 0.0%  | 73.6% | -25.0%  | 0.1    | 2.9    |
| 2023-2025  | 6.0%  | 73.6% | -47.0%  | 0.1    | 2.4    |

    *Analysis:*
    *   The negative Alpha values across all periods show the company is underperforming the benchmark index.
    *   The Beta values close to 0 suggest that the stock price movements are not highly correlated with the overall market (S&P 500).
    *   The MDD is very high, indicating significant risk.
    *   The decrease in market cap shows the company is losing value.

**2. Recent Stock Price Movement**

*   **Current Price:** 5.52
*   **Last-market:**
    *   Price: 5.52
    *   Previous Close: 5.77
    *   Change: -4.33% (significant drop)
*   **Moving Averages:**
    *   5-day MA: 5.608
    *   20-day MA: 5.8165
    *   60-day MA: 5.3184

    *Analysis:* The stock price has recently dropped significantly (-4.33%). The 5-day and 20-day moving averages are above the current price, suggesting a short-term downward trend. The price is above the 60-day MA, indicating a potential mixed longer-term trend, but the recent drop is concerning.

**3. Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.3285 (Low Risk)
*   **RSI:** 39.41
*   **PPO:** -0.6682
*   **Hybrid Signal:** cash_69%_Sell 0.7% of holdings (11 shares - Caution - MRI:0.33) (Cash Ratio: 69% on 2025-08-07)
*   **Recent (20-day) Relative Divergence Change:** -2.4 (Decreasing)
*   **Expected Return:** -1024.9%

    *Analysis:*
    *   The MRI indicates a low-risk environment, seemingly contradicting other negative indicators.
    *   The RSI is below 40, indicating that the stock is nearing oversold conditions, which sometimes precedes a price correction.
    *   The negative PPO suggests a short-term downward trend.
    *   The Hybrid Signal recommends reducing holdings and increasing cash, which is a bearish signal.
    *   The decreasing relative divergence reinforces the short-term negative trend compared to the S&P 500.
    *   The extremely negative expected return suggests significant skepticism about the stock's future performance.

**4. Recent News & Significant Events**

*   [2025-08-17] - RXRX has recently made headlines due to major business developments, regulatory changes, or market events.
*   [2025-08-16] - Analysts are discussing RXRX's recent performance and its outlook in the context of industry trends and global economic factors.
*   [2025-08-15] - RXRX's stock has shown notable volatility, influenced by recent news, earnings reports, or executive actions.
*   [2025-08-19] - Market experts highlight both risks and opportunities for RXRX, advising investors to monitor recent news and company announcements.

    *Analysis:* The news indicates volatility and ongoing discussions about the company's performance, suggesting potential catalysts for price movement. Monitoring specific announcements is crucial.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출     |
|------------|-------|----------|
| 2025-08-05 | -0.41 | 0.02 B$  |
| 2025-05-05 | -0.50 | 0.01 B$  |
| 2024-11-06 | -0.34 | 0.03 B$  |
| 2024-08-08 | -0.40 | 0.01 B$  |
| 2025-08-05 | -0.40 | 0.01 B$  |

    *Analysis:* The company has consistently reported negative EPS, indicating a lack of profitability. Revenue figures are low and inconsistent.

**6. Financial Information**

Revenue and Profitability:

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-06-30 | \$0.02B    | -5.54%        |
| 2025-03-31 | \$0.01B    | -47.31%       |
| 2024-12-31 | \$0.00B    | -183.62%      |
| 2024-09-30 | \$0.03B    | 53.69%        |
| 2024-06-30 | \$0.01B    | 36.14%        |

Capital and Profitability:

| Quarter    | Equity     | ROE       |
|------------|------------|-----------|
| 2025-06-30 | \$0.92B    | -18.70%   |
| 2025-03-31 | \$0.93B    | -21.68%   |
| 2024-12-31 | \$1.03B    | -17.29%   |
| 2024-09-30 | \$0.52B    | -18.27%   |
| 2024-06-30 | \$0.58B    | -16.69%   |

    *Analysis:*
    *   Revenue is low and fluctuates significantly.
    *   Profit margins are predominantly negative, indicating a lack of profitability.  The exceptions in 2024 Q2 and Q3 may be due to one-time events or accounting adjustments.
    *   ROE is consistently negative, indicating poor returns on equity.
    *   Equity has fluctuated.

**7. Overall Analysis**

Based on the provided data, RXRX (Recursion Pharmaceuticals Inc.) exhibits several concerning trends:

*   **Significant Underperformance:**  The stock has significantly underperformed the S&P 500, with a large negative divergence.
*   **Lack of Profitability:** Consistent negative EPS, poor profit margins, and negative ROE indicate fundamental financial challenges.
*   **Negative Sentiment:** Technical indicators and hybrid signals suggest caution and potential further price declines.
*   **Volatility:** Recent news suggests the stock is subject to volatility, requiring careful monitoring.

**Conclusion:**

The analysis suggests a bearish outlook for RXRX. Investors should exercise extreme caution.  The company's lack of profitability, underperformance relative to the market, and negative technical signals warrant significant concern. While the MRI indicates low market risk, it's important to note that this only reflects the overall market risk and may not accurately represent the specific risks associated with RXRX. Recent news and market discussions suggest ongoing uncertainty and potential catalysts for price movement. Close monitoring of company announcements and further financial data is critical.

